Presentation of preclinical data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting and additional clinical update

Read More

Preclinical and clinical data on RVU120 presented at the 2023 American Society of Hematology (ASH) Annual Meeting

Read More

Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023

Read More

Ryvu Therapeutics Q3 2023 Financial Report

Read More

Clinical and preclinical data on RVU120 to be presented at the American Society of Hematology (ASH) Annual Meeting

Read More

Ryvu presents updated clinical Phase I/II data of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the ESMO Congress 2023 together with the RVU120 Development Plan update

Read More

Conclusion of a Clinical Trial Financial Support agreement for an investigator-initiated Phase II RVU120 study in Low-Risk Myelodysplastic Syndromes

Read More

RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023

Read More

Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Read More

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Read More

Conclusion of an amendment to global License Agreement with Menarini Group

Read More

Ryvu Therapeutics H1 2023 Financial Report

Read More

Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology

Read More

Conclusion of a financing agreement with the Medical Research Agency

Read More

Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology

Read More

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

Read More

Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology

Read More

Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials

Read More

Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company

Read More

Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.

Read More